Table 3.
Associations between genetic risk scores and TNFi treatment response (achieving good/moderate EULAR response vs no) in overall RA, as well as in ACPA-positive RA and ACPA-negative RA
| GRS | Overall RA | ACPA-positive RA | ACPA-negative RA |
|---|---|---|---|
| GRS76SNPs | |||
| Linear | 0.96 (0.81–1.14) | 1.00 (0.82–1.22) | 0.89 (0.56–1.42) |
| Q1 | Reference | Reference | Reference |
| Q2 vs Q1 | 0.68 (0.31–1.50) | 1.00 (0.36–2.81) | 0.66 (0.17–2.54) |
| Q3 vs Q1 | 0.77 (0.37–1.60) | 1.07 (0.42–2.71) | 0.60 (0.15–2.36) |
| Q4 vs Q1 | 0.79 (0.39–1.57) | 1.06 (0.44–2.55) | 0.95 (0.23–3.93) |
| GRSHaplotype | |||
| Linear | 0.92 (0.77–1.12) | 0.96 (0.76–1.20) | 1.30 (0.80–2.12) |
| Q1 | Reference | Reference | Reference |
| Q2 vs Q1 | 1.15 (0.51–2.61) | 0.76 (0.22–2.65) | 2.35 (0.67–8.20) |
| Q3 vs Q1 | 1.05 (0.52–2.12) | 0.89 (0.30–2.65) | 2.19 (0.58–8.30) |
| Q4 vs Q1 | 0.99 (0.48–2.02) | 0.84 (0.27–2.54) | 3.53 (0.88–14.22) |
| Any SE | 0.79 (0.59–1.06) | 0.84 (0.59–1.20) | 1.07 (0.53–2.17) |
Data presented as odds ratio (95% confidence interval)
ACPA anti-citrullinated protein/peptide antibodies, GRS genetic risk score, RA rheumatoid arthritis, Q quartile, SE shard epitope, TNFi tumor necrosis factor inhibitor, EULAR European League Against Rheumatism